PMID- 34803667
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211123
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 12
DP  - 2021
TI  - Evaluation of Efficacy and Safety for Kanglaite Injection in the Control of the 
      Malignant Pleural Effusions via Thoracic Perfusion: A Systematic Review and 
      Meta-Analysis of Randomized Controlled Trials.
PG  - 694129
LID - 10.3389/fphar.2021.694129 [doi]
LID - 694129
AB  - Background: Kanglaite injection (KLTI) is a traditional Chinese medicine (TCM) 
      preparation with anti-tumor activity, which has been used to treat malignant 
      tumors in China. The purpose of this study was to evaluate the efficacy and 
      safety of intrapleural infusion with KLTI in the treatment of malignant pleural 
      effusion (MPE). Methods: Randomized controlled trials (RCTs) on the efficacy and 
      safety of intrathoracic infusion with KLTI in the treatment of MPE were searched 
      from the PubMed, EMBASE, the Cochrane Library, CNKI, VIP, Wanfang and CBM 
      databases. The primary outcome was objective remission rate (ORR). Secondary 
      outcomes included quality of life (QOL) and incidence of adverse events (AEs). 
      The Stata15.1 software and RevMan5.3 software were used to calculate risk ratios 
      (RR) at 95% confidence intervals (CI) and conduct the meta-analysis. Results: 
      This meta-analysis included 20 RCTs, involving 1,291 patients. The ORR of 
      intrapleural infusion with KLTI + chemotherapy drugs in the treatment of MPE was 
      higher than that of chemotherapy alone (RR) 1.23; 95%CI; 1.11-1.36, I (2) = 0%, z 
      = 3.876, p = 0.000]. When KLTI is combined with cisplatin or KLTI 200 ml is used 
      in every time, it is more advantageous to improve ORR. Moreover, compared with 
      intrapleural infusion of chemotherapy drugs alone, KLTI combined with 
      chemotherapy drugs significantly improved the QOL of patients with MPE (RR 1.28; 
      95%CI; 1.70-1.53, I (2) = 0%, z = 2.70, p = 0.007). In addition, the 
      participation of KLTI reduced the gastrointestinal reaction (RR 0.79; 95% CI; 
      0.66-0.96; I (2) = 0%, z = 2.37, p = 0.018) and renal damage (RR 0.468; 95% CI; 
      0.23-0.945, I (2) = 0%, z = 2.11, p = 0.035) caused by chemotherapy drugs, but 
      did not increase other adverse reactions (p > 0.05). Conclusion: The efficacy and 
      safety of traditional chemotherapy drugs plus KLTI was superior to traditional 
      chemotherapy drugs alone via intrapleural injection in controlling MPE, which 
      suggested that KLTI can be used to treat MPE. However, a more rigorous RCT should 
      be designed and completed before it is widely recommended.
CI  - Copyright (c) 2021 Zhu, Wang, Li, Zhang, Gao, Zhang, Xu, Hu, Dai and Chen.
FAU - Zhu, Guanghui
AU  - Zhu G
AD  - Guanganmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
AD  - Graduate school, Beijing University of Chinese Medicine, Beijing, China.
FAU - Wang, Xinmiao
AU  - Wang X
AD  - Guanganmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
FAU - Li, Jie
AU  - Li J
AD  - Guanganmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
FAU - Zhang, Ying
AU  - Zhang Y
AD  - Guanganmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
FAU - Gao, Ruike
AU  - Gao R
AD  - Guanganmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
FAU - Zhang, Xiaoxiao
AU  - Zhang X
AD  - Guanganmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
FAU - Xu, Bowen
AU  - Xu B
AD  - Guanganmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
AD  - Graduate school, Beijing University of Chinese Medicine, Beijing, China.
FAU - Hu, Jiaqi
AU  - Hu J
AD  - Guanganmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
AD  - Graduate school, Beijing University of Chinese Medicine, Beijing, China.
FAU - Dai, Minghao
AU  - Dai M
AD  - School of Pharmacy, Peking University Health Science Center, Beijing, China.
FAU - Chen, Jiayang
AU  - Chen J
AD  - Traditional Chinese Medicine Department, Cancer Hospital Chinese Academy of 
      Medical Sciences, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211103
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8595202
OTO - NOTNLM
OT  - chemotherapeutic drugs
OT  - kanglaite injection
OT  - malignant pleural effusion
OT  - meta-analysis
OT  - pleural perfusion
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/11/23 06:00
MHDA- 2021/11/23 06:01
PMCR- 2021/11/03
CRDT- 2021/11/22 06:39
PHST- 2021/04/12 00:00 [received]
PHST- 2021/10/19 00:00 [accepted]
PHST- 2021/11/22 06:39 [entrez]
PHST- 2021/11/23 06:00 [pubmed]
PHST- 2021/11/23 06:01 [medline]
PHST- 2021/11/03 00:00 [pmc-release]
AID - 694129 [pii]
AID - 10.3389/fphar.2021.694129 [doi]
PST - epublish
SO  - Front Pharmacol. 2021 Nov 3;12:694129. doi: 10.3389/fphar.2021.694129. 
      eCollection 2021.